Skip to content

13F-HR filed by Euclidean Capital LLC

Euclidean Capital LLC filed this 13F-HR for the quarter ended 2023-09-30, filed 2023-11-14, with 12 holding rows worth $458,129,928.

Accession
0001012975-23-000467
Filed
2023-11-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q3 2023

A holdings report, 12 entries on the cover page, a total value of $458,129,928 stated on the cover page (in dollars after the unit check, H1), rows summing to $458,129,928 with VALUE read as dollars as filed, 13F file number 028-20777. A later restatement replaced it, so the quarter does not use it. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
SPDR GOLD TR78463V107GOLD SHS1,062,500$182,165,625dollars as filed
ISHARES TR46429B598MSCI INDIA ETF2,425,144$107,239,868dollars as filed
SPY78462F103SHS246,250$105,266,950dollars as filed
PMV PHARMACEUTICALS INC69353Y103COM2,627,643$16,133,728dollars as filed
RAPT THERAPEUTICS INC75382E109COM657,899$10,934,281dollars as filed
23ANDME HOLDING CO90138Q108CLASS A COM10,243,122$10,014,700dollars as filed
ALECTOR INC014442107COMMON STOCK1,307,858$8,474,920dollars as filed
FOGHORN THERAPEUTICS INC344174107COMMON STOCK1,573,761$7,868,805dollars as filed
ORIC PHARMACEUTICALS INC68622P109COM989,410$5,985,931dollars as filed
TENAYA THERAPEUTICS INC87990A106COM1,015,705$2,590,048dollars as filed
NGM BIOPHARMACEUTICALS INC62921N105COM992,168$1,061,620dollars as filed
Surrozen, Inc.86889P109COM802,963$393,452dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001012975-23-000467this filing2023-11-14acceptance time not in the bulk data set
13F-HR/A 0001012975-23-000496 base2023-12-01acceptance time not in the bulk data set